Orso Bio is a biotechnology company that specializes in developing and commercializing novel therapies for rare diseases. The company leverages its proprietary technology platform to discover and advance treatments that address unmet medical needs.

Orso Bio

OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. 

National Institute of Diabetes and Digestive and Kidney Diseases

OrsoBio

Thanks to Brian K. Buntz and Drug Discovery & Development for highlighting our programs and complementarity to #glp1 receptor agonists. https://lnkd.in/gBBEVvrd


At AASLD’s #tlm23 this weekend, OrsoBio collaborators Yasmine Liu, Ph.D., Prof. Johan Auwerx, and Takanori Takebe  presented beautiful data showing the benefits of ACMSD inhibition with TLC-065 to increase hepatic NAD+, reduce inflammation and fibrosis, and enhance mitochondrial function in mouse hepatocytes, a diet-induced thermoneutrality mouse model of NASH, and in iPSC-derived human liver organoids from NASH patients. These data support the potential of ACMSD inhibition to improve liver disease due to #NASH and other etiologies.

Read more here: https://lnkd.in/gq7-zvcr

OrsoBio roars with $60m to treat metabolic disorders

Company targets metabolism with therapies to restore energy stability and prevent organ dysfunction.

#longevity #investment #obesity

Today OrsoBio announced a $60M Series A financing to support advancement of our metabolic portfolio for the treatment of obesity and related disorders. We're thrilled to welcome our new investors, Longitude Capital, Enavate Sciences, and Eli Lilly and Company, and for the continued support from our existing investors, Samsara BioCapital and NuevaBio, as we embark on the next stage of our journey. 

Read the announcement here: https://lnkd.in/gEBDii36

We're excited to present Phase 1 data for our liver-targeted LXR inverse agonist, TLC-2716, at #AHA23 this week. The data demonstrate dose-dependent improvements in atherogenic lipids (e.g., TGs, LDL-C, LDL particles, apoB) and support Phase 2 development in severe hypertriglyceridemia and #NASH. Read more here: https://bwnews.pr/3sweuii 

COM:ORSOBIO

Orso Bio